All Posts
Protected: DES Pharma Consulting and Adept Packaging Announce Strategic Alliance to Integrate CMC Strategy with Pharmaceutical Packaging Execution
There is no excerpt because this is a protected post.
June 30, 2026
There is no excerpt because this is a protected post.
For AAV gene therapy programs, two analytical questions sit at the center of every CMC
For biologics such as monoclonal antibodies, recombinant proteins, vaccines, and advanced cell and gene therapies,
The Drug Supply Chain Security Act (DSCSA) reshaped how pharmaceutical products move through the U.S.
A pre-IND meeting is one of the highest-leverage interactions a biologics sponsor will have with
Biotech startups operating under FDA-regulated conditions face a deceptively simple question: when we adopt a
Transitioning an AAV gene therapy program from adherent cell culture to a suspension platform is
Grant Writing · Pharma & Drug Development · Complete Guide The Complete Guide
When a pharmaceutical or life sciences company receives a Form 483, Warning Letter, or Consent
Pharmacovigilance consulting has become a cornerstone of modern drug development and post-market surveillance. As regulatory
Start building reliable, high-quality drug development programs today.